Efremov V.V. 1
Kushnaryova V.V. 2
Sergienko V.S. 3
Bakuzova D.V. 1
1 The Rostov state medical university
2 The City Hospital №6 of Rostov-on-Don
3 The City Рoliclinic №3 of Shahtyi
The article explored the impact of systemic enzyme therapy wobenzyms cognitive function and parameters of lipid metabolism in the 40 patient of chronic cerebral ischemia atherosclerotic and hypertensive cerebral genesis. Against the backdrop of 8-week therapy wobenzyms authentically decreased total cholesterol from 6,13±0,32 mmol/l to 5,39±0,22 mmol/l, cholesterol LDL with 3,61±0.28 mmol/l to 2,74±0,15 mmol/l, the atherogenicity coefficient with 2,86±0,34 to 2,01±0,17 after treatment with an additional appointment wobenzyms length of time the trial was shorter, and Schulte cognitive score higher compared to patients receiving standard therapy. Supplementation wobenzyms to neurometabolictherapy in patients with chronic cerebral ischemia contributes to a more favorable changes in cognitive function and normalization of lipid profile that enhances efficacy standard therapy/